TEMOZOLOMIDE IN TREATMENT OF ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE

假设替莫唑胺在6个月内产生20%的进展 初治间变性星形细胞瘤患者的无瘤生存率 复发具体目的是：1）确定 替莫唑胺定义为6个月时的无进展生存期， 该药剂口服给药时的安全性，每天一次，持续五天， 每28天重复一次，用于治疗间变性患者 星形细胞瘤首次复发; 2）描述 研究中招募的患者的寿命（HQL）; 3）评估人群- 接受替莫唑胺的患者中的基于药代动力学的研究; 4）评估 所有接受替莫唑胺治疗的患者的总生存率。

It is hypothesized that Temozolomide produceds a 20% 6 month progression free-survival rate in patients with anaplastic astrocytoma at first relapse. The specific aims are: 1) To determine the efficacy of temozolomide defined as progression-free survival at six months and the safety of this agent when administered orally, once a day, for five days, repeated every 28 days in the treatment of patients with anaplastic astrocytoma at first relapse; 2) To describe the health-related quality of life (HQL) of patients enrolled in the study; 3) To assess population- based pharmacokinetics in patients receiving temozolomide; 4) To assess overall survival for all patients receiving temozolomide.